Guizhou Sinorda Biotechnology
Guizhou Sinorda Biotechnology

—since

2010

Committed to becoming a leader in innovative therapies for digestive tract diseases and tumors

图标

Core business

Focusing on the development and industrialization of innovative drugs for digestive tract diseases, tumor immunity and autoimmune diseases.

图标

Cultural concept

With the bio-innovative drug technology platform as the core, we will continue to explore drug research and development breakthroughs in the fields of digestive tract, tumor and autoimmune diseases, and adhere to the iterative upgrading of technologies and products.

图标

Corporate mission

Deeply cultivate innovative drug research and development and industrialization, meet clinical treatment needs with high-quality new drugs, and safeguard patient health.

ABOUT US

Guizhou Sinorda Pharmaceutical Co., Ltd.

Sinorda established in 2010 and is a biomedical innovation company in the commercialization stage. The company focuses on the research and development and industrialization of innovative drugs for digestive tract diseases, tumor immunity and autoimmune diseases. The company's self-developed new drug for the treatment of gastric acid-related diseases, class 1.1 linaprazan glureta (X842), has been successfully approved for marketing, commercialization and industrialization. The sentinel lymph node T cell project for the treatment of solid tumors has clinical IIT research results for a variety of tumors. In addition, the company has a number of early-stage product pipelines, including double-specific antibodies for the treatment of autoimmune disease IBD. The company has developed rapidly through extensive cooperation with domestic and foreign pharmaceutical companies and R & D institutions, and is committed to becoming a valuable innovative drug company in China.

View more

30

+ Item

Accumulatively obtained domestic and foreign patents

23

Billion USD

Global acid-related disease drugs market size

142.3

Billion USD

Global autoimmune disease drugs market size

235

Billion USD

Global oncology drug market size

img

Product Classification

———

Product

Scientific research and innovation · Quality service

Layers of control, excellence, we work hard to reassure you

Product Center

Linaprazan glurate capsules

Gastroesophageal reflux disease (GERD) is a common digestive disorder characterized by the backflow of stomach contents—such as gastric acid and bile—into the esophagus, leading to uncomfortable symptoms and/or complications.

Specifications: 50mg

Adaptation: Gastroesophageal Reflux Disease

Registration Category: Chemical Drug Category 1

Approval number: National Medical Product Approval Number H20240042

View more
Linaprazan glurate capsules

TECHONLOGY

Technology Platform

Lymph-T Exp® – Lymph Node Dry T Cell Expansion Technology Platform

Using Sinorda's proprietary T-cell production technology, it is possible to expand anti-tumor active T cells derived from lymph nodes to over 10 billion cells within approximately two weeks (an expansion of more than 5,000-fold), while maintaining the polyclonality, tumor-specificity, and T-cell stemness of the cell product. The success rate for preparation exceeds 90%.

Immune OrganoHub Organoid Drug Efficacy Assessment Platform

In 2025, the FDA announced its plan to gradually eliminate animal testing requirements for monoclonal antibodies and other drugs, encouraging the use of emerging technologies such as AI-driven computational models, organoids, and organ-on-a-chip systems as viable alternatives. Meanwhile, China’s “14th Five-Year” Plan also prioritizes the development of organoid platforms, and the CDE has unveiled several guiding principles aimed at promoting the adoption of organoids in drug research and development.

Immun-marker Hunt: Immune Marker Discovery Platform

By identifying, quantifying, and dynamically analyzing the composition, status, and distribution of patients' immune cells and cytokines, we can infer the immune state of the tumor microenvironment, providing predictive insights for evaluating cancer treatment outcomes and developing personalized immunotherapy strategies.

Neo-Pred® – Neoantigen Prediction Platform

Neo-Pred® is an intelligent neoantigen prediction platform developed by Sinorda Pharma. It can read various high-throughput sequencing data, enabling rapid and accurate prediction of tumor neoantigens.

Animal Pharmacological Screening Platform

Focused on providing a pharmacodynamic evaluation platform for drug development, covering areas such as oncology, cancer immunology, and autoimmune diseases. Our experimental animal models include rats and mice.

SINORDA

SINORDA

Therapeutics for Unmet Medical Needs

NEWS CENTER

Blog Center

Sinorda Pharmaceutical and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

Sinorda Pharmaceutical and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

SHANGHAI, Jan. 29, 2026–Sinorda Pharmaceutical, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoimmune diseases, today announced it has entered into a strategic collaboration agreement with WuXi Biologics (2269.HK). The partnership is specifically designed to accelerate the preclinical pharmacology studies and clinical manufacturing of SND006, Sinorda’s independently developed, novel bispecific antibody.

China-developed Innovative Drug "Linaprazan Glurate Capsules" Launches Nationwide with First Batch Shipment, Offering New Option for Patients with Reflux Esophagitis

China-developed Innovative Drug "Linaprazan Glurate Capsules" Launches Nationwide with First Batch Shipment, Offering New Option for Patients with Reflux Esophagitis

On January 5, 2026, the first batch of Linaprazan Glurate Capsules (trade name: Xinlian®), a Class 1 innovative drug independently developed by Sinorda Biotechnology , was shipped for nationwide launch. This milestone marks the official clinical application of the world’s first Potassium-Competitive Acid Blocker (P-CAB) with an ester bond structure, bringing a brand-new treatment option to domestic patients suffering from reflux esophagitis.

Sinorda and HuaDong Pharma Enter into Commercialization Partnership for Linaprazan Glurate, a novel gastric acid inhibitor

Sinorda and HuaDong Pharma Enter into Commercialization Partnership for Linaprazan Glurate, a novel gastric acid inhibitor

Guiyang, China – December 7 – Guizhou Sinorda Biotech Co., Ltd., its wholly-owned subsidiary Shanghai Sinorda Medicine Tech. Co., Ltd., and Jiangsu Sinorda Biopharma Co., Ltd. (collectively, "Sinorda") announced that has entered into an exclusive commercialization agreement with Huadong Medicine (Hangzhou) Co., Ltd., which is wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZSE: 000963, "HuaDong Pharma") , for Mainland China for Sinorda's product Linaprazan Glurate Capsules and other dosage forms.

The Phase III clinical study of Linaprazan glurate—the National Investigators' Meeting—was held in Hangzhou, bringing together experts to collaboratively explore innovative treatment strategies for duodenal ulcers and Helicobacter pylori eradication.

The Phase III clinical study of Linaprazan glurate—the National Investigators' Meeting—was held in Hangzhou, bringing together experts to collaboratively explore innovative treatment strategies for duodenal ulcers and Helicobacter pylori eradication.

On November 8, 2025, in Hangzhou—The national investigator meeting for the two Phase III clinical trials of "Linaprazan glurate (X842) Capsules," hosted by Shanghai Sinorda Pharmaceutical Technology Co., Ltd. (hereinafter referred to as Sinorda) and co-organized by Anhui CTSMED Pharmaceutical Technology Co., Ltd. (hereinafter referred to as CTSMED), was successfully held in Hangzhou.

2026-01-29 08:54

Sinorda Pharmaceutical and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

SHANGHAI, Jan. 29, 2026–Sinorda Pharmaceutical, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoimmune diseases, today announced it has entered into a strategic collaboration agreement with WuXi Biologics (2269.HK). The partnership is specifically designed to accelerate the preclinical pharmacology studies and clinical manufacturing of SND006, Sinorda’s independently developed, novel bispecific antibody.

2026-01-05 17:33

China-developed Innovative Drug "Linaprazan Glurate Capsules" Launches Nationwide with First Batch Shipment, Offering New Option for Patients with Reflux Esophagitis

On January 5, 2026, the first batch of Linaprazan Glurate Capsules (trade name: Xinlian®), a Class 1 innovative drug independently developed by Sinorda Biotechnology , was shipped for nationwide launch. This milestone marks the official clinical application of the world’s first Potassium-Competitive Acid Blocker (P-CAB) with an ester bond structure, bringing a brand-new treatment option to domestic patients suffering from reflux esophagitis.

2025-12-10 18:28

Sinorda and HuaDong Pharma Enter into Commercialization Partnership for Linaprazan Glurate, a novel gastric acid inhibitor

Guiyang, China – December 7 – Guizhou Sinorda Biotech Co., Ltd., its wholly-owned subsidiary Shanghai Sinorda Medicine Tech. Co., Ltd., and Jiangsu Sinorda Biopharma Co., Ltd. (collectively, "Sinorda") announced that has entered into an exclusive commercialization agreement with Huadong Medicine (Hangzhou) Co., Ltd., which is wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZSE: 000963, "HuaDong Pharma") , for Mainland China for Sinorda's product Linaprazan Glurate Capsules and other dosage forms.

2025-11-08 13:38

The Phase III clinical study of Linaprazan glurate—the National Investigators' Meeting—was held in Hangzhou, bringing together experts to collaboratively explore innovative treatment strategies for duodenal ulcers and Helicobacter pylori eradication.

On November 8, 2025, in Hangzhou—The national investigator meeting for the two Phase III clinical trials of "Linaprazan glurate (X842) Capsules," hosted by Shanghai Sinorda Pharmaceutical Technology Co., Ltd. (hereinafter referred to as Sinorda) and co-organized by Anhui CTSMED Pharmaceutical Technology Co., Ltd. (hereinafter referred to as CTSMED), was successfully held in Hangzhou.

View more
Guizhou Sinorda Pharmaceutical Co., Ltd.

Email: info1@sinorda.com

Zip code: 550018

Address: Guizhou Province Guiyang City National High-tech Zone West R & D Base

Consultation Hotline

0851-84847104

→
%{tishi_zhanwei}%
QR code
Business license
Label | Website construction: www.300.cn-GuiYang